NEURALINK UNVEILS HUMAN BRAIN IMPLANT, ARBAUGH PLAYS GAMES.

Neuralink introduced its first human brain implant recipient, Noland Arbaugh, a 29-year-old paralyzed after a diving accident, showcasing his ability to play online games using his thoughts. Co-founded by Elon Musk, Neuralink aims to enable paralyzed individuals to control devices through brain-computer interfaces, interpreting intentions from brain signals. Arbaugh, demonstrating the technology on X, described learning to control a cursor intuitively. Neuralink, which received FDA approval for human trials, has been criticized for its secrecy and treatment of test animals. Despite controversies, Arbaugh praised the device’s impact on his life, mentioning minor issues but overall expressing optimism for the future. The device, implanted by a surgical robot, remains cosmetically hidden and works by translating brain signals into commands. Competitors like Synchron are also developing similar technologies, though no brain-computer interface has yet received FDA approval, remaining experimental. (Wired)

NVIDIA LEADS WITH PROJECT GR00T, ADVANCING HUMANOID ROBOTS.

Nvidia is spearheading the development of humanoid robots with Project GR00T, aiming to integrate advanced AI into physical forms to create versatile, autonomous robotic assistants. The initiative seeks to advance artificial general intelligence (AGI) by allowing robots to understand and execute tasks based on multimodal instructions, enhancing their interaction with the real world. Nvidia’s CEO, Jensen Huang, emphasized the potential ease of developing humanoid robots due to the abundance of human movement data available for imitation learning, alongside the practicality of robots mimicking human form to navigate and utilize human-designed environments. Alongside GR00T, Nvidia introduced Jetson Thor, a powerful computing platform designed to support such AI-driven robots. Despite the innovative push towards embodied AGI, ethical concerns arise regarding job displacement and the prioritization of technological advancement over ethical considerations. Nvidia’s collaboration with various companies aims to foster a thriving ecosystem for humanoid robotics, potentially revolutionizing how robots integrate into society. (Ars Technica)

If you’re enjoying the Daily Dose, sign up for the Daily Dose Newsletter and get the morning’s best science news from around the web delivered straight to your inbox? It’s easy like Sunday morning.

FARM TO FEED TACKLES KENYA’S FOOD LOSS, SECURES FUNDING.

In Kenya, where food loss ranges between 20% to 40%, startups like Farm to Feed are emerging to address this issue by creating market opportunities for small-scale farmers, who contribute to 75% of the country’s agricultural output. Farm to Feed, launched in 2021 by Claire Van Enk and her co-founders, aggregates imperfect farm produce, which is often rejected by traditional distributors due to size or shape, and sells it to businesses like restaurants and food processors. This initiative not only opens new revenue streams for farmers but also tackles food security and climate change by reducing food loss and the resultant methane emissions from rotting produce. The startup has raised $1 million in funding and plans to expand its sales channels and utilize sustainable transport solutions. Additionally, Farm to Feed is developing a data platform to better understand and mitigate factors behind food loss, exploring value addition to enhance profitability, and investigating the potential of entering the carbon market by selling carbon offset credits. (TechCrunch)

IMMUNOACT LAUNCHES AFFORDABLE CAR-T THERAPY, CHALLENGES GLOBAL COSTS.

An Indian biotech company, ImmunoACT, has made significant strides in producing a cost-effective version of CAR-T cell therapy, a groundbreaking treatment for blood cancers, with their product, NexCAR19, costing between $30,000 and $40,000. This is a fraction of the cost of similar therapies available globally, which range between $370,000 and $530,000. Approved for therapeutic use in India, NexCAR19 is now being administered to patients, offering hope particularly for those for whom traditional treatments have failed. The therapy, which has shown promise in treating autoimmune diseases and brain cancer, modifies patients’ T cells to target cancer cells more effectively. Early clinical trials have demonstrated a high response rate, with significant tumor reduction in a majority of participants. The therapy’s affordability and safety profile compared to FDA-approved counterparts highlight India’s potential to make advanced cellular therapies more accessible worldwide, while also prompting reevaluation of production costs in high-income countries. ImmunoACT’s achievements are not just a breakthrough in affordable healthcare but also a challenge to global markets to reduce the costs of life-saving treatments. (Nature)

STUDY CHALLENGES US MATERNAL MORTALITY RATE INCREASE, CDC DISAGREES.

The U.S. is facing a contentious debate over its maternal mortality rate (MMR), historically criticized for being exceptionally high, particularly among Black and Native American women. A recent study published in the American Journal of Obstetrics and Gynecology (AJOG) by University of British Columbia and Rutgers University epidemiologists challenges the perceived escalation of the U.S. MMR, attributing the reported tripling over two decades primarily to a change in death certificate protocols introduced by the CDC. This change, a “pregnancy checkbox,” was meant to improve the reporting accuracy but is argued to have led to overreporting by misclassifying deaths unrelated to pregnancy. The CDC and other experts have critiqued the study’s methodology, maintaining that the checkbox reveals previously unrecorded maternal deaths, essential for understanding and addressing the issue. Despite disagreement on the numbers, there is consensus on the disproportionate impact on women of color and the need for improved accuracy and communication in maternal mortality reporting. (Science)

ANCIENT HUMANS SURVIVED VOLCANO BY SWITCHING TO FISHING, STUDY SUGGESTS.

In 2002, a team of paleoanthropologists in northwestern Ethiopia discovered signs of ancient human life dating back 74,000 years at a site called Shinfa-Metema 1. Their findings, detailed in a Nature publication, suggest these early humans were highly adaptable, surviving a massive volcanic eruption by altering their food sources from hunting big game to fishing. This adaptability may have been key to humans’ successful expansion out of Africa into Eurasia. The site revealed thousands of animal bones, arrowheads (potentially the earliest evidence of archery), and fragments of ostrich eggshells. The eruption of the Toba volcano had drastically changed their environment, shortening rainy seasons and reducing water levels, prompting these humans to switch from hunting to fishing. This evidence challenges the notion that humans expanded out of Africa solely during wet periods using “green highways,” suggesting instead that they could rapidly devise new survival strategies, like utilizing “blue highways” of rivers for fishing during dry periods. This hypothesis, while debated, offers fresh insight into human adaptability and migration patterns. (New York Times)

Thanks for reading. Let’s be careful out there.

WORDS: The Biology Guy.

IMAGE CREDIT: Neuralink.